Whiteboard Video: The Mechanisms of Action of Tyrosine Kinase Inhibitors

Whiteboard Video: The Mechanisms of Action of Tyrosine Kinase Inhibitors

HMP CME

2 years
1,028 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Tyrosine kinase inhibitors (TKIs) are orally active, small molecules that exhibit antitumor activity by targeting enzymes that play a critical role cellular functions, including modulation of growth factor signaling, proliferation, carcinogenesis, and cell differentiation. Several TKIs, including sorafenib and regorafenib, have already been approved for first and second line treatment of hepatocellular carcinoma (HCC), respectively. Further, a plethora of novel TKIs such as lenvatinib and cabozantinib are being investigated for their potential use in the therapeutic management of HCC. In this whiteboard video, Dr. Richard S. Finn of the UCLA Geffen School of Medicine describes the role of TKIs in the therapeutic management of HCC. Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7285 © 2018 Imedex, LLC.
Up Next Autoplay